composition
Each injection contains Bevacizumab 100 mg /4 ml and 400 mg/ 16 ml concentrate for intravenous infusion
indications
Colorectal Cancer (mCRC), Lung Cancer (NSCLC), Glioblastoma (GBM), Renal Cell Carcinoma, Cervical Cancer and Ovarian cancer
Therapeutic Focus
Oncology
